Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Symptom Improvement Appears Similar With Momelotinib Vs Ruxolitinib in Myelofibrosis

June 17th 2021

Momelotinib can provide clinically relevant and comparable improvement in overall symptom burden and individual symptom items compared with ruxolitinib in patients with intermediate- and high-risk JAK inhibitor–naïve myelofibrosis.

FDA Approves Avapritinib for Advanced Systemic Mastocytosis

June 16th 2021

The FDA has approved avapritinib (Ayvakit) for the treatment of adult patients with advanced systemic mastocytosis, including those with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast cell leukemia.

Improvements in Cardiovascular Risk Management Needed for MPN

June 11th 2021

Although cardiovascular health of patients with myeloproliferative neoplasms was relatively good, an estimated 11% to 22% of patients were not prescribed appropriate medications for management of comorbidities associated with thrombotic risk.

Dr. Mesa on Data With Momelotinib in Transfusion Independence Responders in Myelofibrosis

June 11th 2021

Ruben A. Mesa, MD, discusses results seen with momelotinib in patients with transfusion-independent myelofibrosis, as demonstrated in the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials.

Dr. Mesa on Achieving Transfusion Independence in Momelotinib-Treated Myelofibrosis

June 10th 2021

Ruben A. Mesa, MD, discusses the importance of achieving transfusion independence with momelotinib in myelofibrosis.

Dr. Bewersdorf on the Role of Allogeneic Transplant in Myelofibrosis

June 10th 2021

Jan Philipp Bewersdorf, MD, discusses the role of allogeneic hematopoietic cell transplant in myelofibrosis.

Week 24 Transfusion Independence With Momelotinib Is Associated With Improved OS in Myelofibrosis

June 10th 2021

Week 24 transfusion independence was associated with an improvement in overall survival vs week 24 transfusion dependence in patients with myelofibrosis who were randomized to momelotinib in the phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials.

Novel Combination Holds Potential to Address All Hallmarks of Myelofibrosis

June 10th 2021

In an effort to build on the efficacy demonstrated with ruxolitinib, investigators are evaluating combination therapies—specifically the dual inhibition of the JAK-STAT and BET pathways using pelabresib, a novel BET inhibitor.

FDA Grants Breakthrough Therapy Designation to Rusfertide for Polycythemia Vera

June 4th 2021

The FDA has granted breakthrough therapy designation to rusfertide as a potential therapeutic option for patients with polycythemia vera to reduce erythrocytosis in those who do not require further treatment for thrombocytosis and/or leukocytosis.

Dr. Yacoub on Next Steps With Parsaclisib Plus Ruxolitinib in Myelofibrosis

June 1st 2021

Abdulraheem Yacoub, MD, discusses next steps with the combination of parsaclisib and ruxolitinib in myelofibrosis.

FDA Grants Priority Review to Pacritinib for Myelofibrosis

June 1st 2021

The FDA has granted priority review to a new drug application for pacritinib as a potential treatment option for patients with myelofibrosis and severe thrombocytopenia, defined as platelet counts less than 50 x 109/L.

Positive Data With Parsaclisib/Ruxolitinib Pave the Way for Phase 3 Studies in Myelofibrosis

May 26th 2021

Abdulraheem Yacoub, MD, discusses the rationale for combining PI3K inhibitors with ruxolitinib in myelofibrosis, the results of the phase 2 study with parsaclisib, and ongoing phase 3 trials evaluating this novel combination.

Dr. Verstovsek on the Rationale for Utilizing Ruxolitinib/Navitoclax in Relapsed/Refractory Myelofibrosis

May 21st 2021

Srdan Verstovsek, MD, PhD, discusses the rationale for utilizing ruxolitinib and navitoclax in patients with relapsed/refractory myelofibrosis.

BLA Resubmitted to FDA for Ropeginterferon Alfa-2b-Njft in Polycythemia Vera

May 19th 2021

The biologics license application seeking the approval of ropeginterferon alfa-2b-njft for use in the treatment of patients with polycythemia vera has been resubmitted to the FDA.

Dr. Verstovsek on Future Research Efforts in MPNs

May 18th 2021

Srdan Verstovsek, MD, PhD, discusses future research efforts for patients with myeloproliferative neoplasms.

Dr. Verstovsek on Real-World Survival Data With Ruxolitinib in Myelofibrosis

May 10th 2021

Srdan Verstovsek, MD, PhD, discusses real-world survival data with ruxolitinib in myelofibrosis.

Dr. Yacoub on Efficacy and Safety Results With Parsaclisib in Myelofibrosis

May 6th 2021

Abdulraheem Yacoub, MD, discusses efficacy and safety results with parsaclisib in myelofibrosis.

Dr. Alkharabsheh on Future Research Directions in MPNs

May 5th 2021

Omar Alkharabsheh, MD, discusses future research directions for the treatment of patients with myeloproliferative neoplasms.

Dr. Verstovsek on the Efficacy of Ruxolitinib Plus CPI-0610 in Myelofibrosis

May 3rd 2021

Srdan Verstovsek, MD, PhD, discusses the efficacy of ruxolitinib in combination with CPI-0610 in myelofibrosis.

Unmet Needs and Looking Ahead in Essential Thrombocythemia

April 21st 2021

Unmet needs and current areas that are being studied in in essential thrombocythemia.